Results 61 to 70 of about 4,861,637 (146)

Advances and Prospects of Stereotactic Radiosurgery and Stereotactic Ablative Body Radiotherapy: Evolving Paradigms in Precision Oncology

Med Research, Volume 2, Issue 1, Page 157-180, March 2026.
The graphical abstract outlines the progressive development and impact of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). Technological Evolution illustrates the transition from brachytherapy with single‐dose, LDR/HDR schedules to fractionated radiotherapy, three‐dimensional conformal radiotherapy (3DCRT) and Gamma Knife ...
Jing Zhang, Wenhao Xu, Weiqing Lu, Yingxuan Lin, Luoxi He, Zonglin Lv, Yiliyaer Nuerrula, Zouting, Zhen Zhang, Hailiang Zhang, Xuejun Ma   +10 more
wiley   +1 more source

Artificial Intelligence–Guided Clinical Decision Support for Immunotherapy in Advanced Hepatocellular Carcinoma: From Benefit–Risk Stratification to Adaptive Management

International Journal of Clinical Practice, Volume 2026, Issue 1, 2026.
Immune checkpoint inhibitor–based regimens have become central to the systemic management of advanced hepatocellular carcinoma (HCC). Nevertheless, substantial heterogeneity persists in treatment efficacy, duration of response, toxicity, and preservation of liver function.
Tian Liang, Anchun Mo, Ke Su
wiley   +1 more source

Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection

, 2022
Oligoprogression is defined as limited metastatic clone resistant to on-going systemic treatment that grows in a background of stable or responding systemic disease.
Marzo, Marco Antonio, D'agostino, Giuseppe, Zucali, Paolo Andrea, Franzese, Ciro, Perrino, Matteo, Badalamenti, Marco, Marini, Beatrice, Scorsetti, Marta, Baldaccini, Davide, De Vincenzo, Fabio   +9 more
core   +1 more source

Interventional oncology: A primer for clinicians on the role of ablation and embolization for solid tumors

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract Interventional radiology (IR) is a rapidly evolving medical field that combines advanced imaging with minimally invasive techniques for both diagnosis and treatment. Interventional oncology (IO), a subspecialty of IR, focuses on the minimally invasive, image‐guided intervention for cancer and cancer‐related conditions.
Mohamed E. Abdelsalam, Kamran Ahrar, Rahul A. Sheth, Ketan Y. Shah, Steven Yevich, Varshana Gurusamy, Bruno C. Odisio, Alda L. Tam, Armeen Mahvash, Peiman Habibollahi   +9 more
wiley   +1 more source

Image-Guided Percutaneous and Transarterial Therapies for Primary and Metastatic Lung Cancer

Technology in Cancer Research & Treatment, 2023
Lung cancer is the leading cause of cancer mortality in the world. A significant proportion of patients with lung cancer are not candidates for surgery and must resort to other treatment alternatives.
Arian Mansur BA, Tushar Garg MD, Juan C. Camacho MD, Peiman Habibollahi MD, F. Edward Boas MD, PhD, Fereshteh Khorshidi MD, Ji Buethe MD, Nariman Nezami MD   +7 more
doaj   +1 more source

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

CA: A Cancer Journal for Clinicians, Volume 76, Issue 1, January/February 2026.
Abstract The therapeutic landscape for renal cell carcinoma (RCC) and urinary tract cancer (UTC) has transformed dramatically, creating complexity in treatment selection and sequencing. The 2025 Advanced Urologic Cancer Consensus Conference was convened to establish evidence‐based expert consensus recommendations for optimal management.
Rana R. McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges, Andrea Apolo, Michael B. Atkins, Rick Bangs, Kathryn E. Beckermann, Joaquim Bellmunt, Stephanie A. Berg, Mehmet A. Bilen, David Braun, Maria I. Carlo, Jason Efstathiou, Matthew Galsky, Petros Grivas, Shilpa Gupta, Naomi Haas, A. Ari Hakimi, Hans Hammers, Daniel Y. C. Heng, Michelle Hirsch, Gopakumar Iyer, Eric Jonasch, Vadim S. Koshkin, Oleksandr N. Kryvenko, Bryan Lewis, Roger Li, Surena Matin, Benjamin Maughan, David F. McDermott, Bradley McGregor, Joshua Meeks, Matthew Milowsky, Robert Motzer, Andrea Necchi, Dan Petrylak, Sima Porten, Thomas Powles, Brian Rini, Brian Shuch, Arlene Siefker‐Radtke, Guru Sonpavde, S. Srikala Sridhar, Cristina Suarez, Chad Tang, Abhishek Tripathi, Michiel S. Van Der Heijden, Martin Voss, Wenxin Xu, Tian Zhang, Jonathan Rosenberg, Toni K. Choueiri   +53 more
wiley   +1 more source

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer

BMC Cancer, 2019
Background Stereotactic irradiation (SBRT) is a standard of care for inoperable stage I lung cancer and brain oligometastases from lung cancer but is controversial for extracranial oligometastases.
Manon Kissel, Isabelle Martel-Lafay, Justine Lequesne, Jean-Christophe Faivre, Cécile Le Péchoux, Dinu Stefan, Victor Barraux, Cédric Loiseau, Jean-Michel Grellard, Serge Danhier, Delphine Lerouge, Christos Chouaid, Radj Gervais, Juliette Thariat   +13 more
doaj   +1 more source

Assessing Second‐Line Treatment Strategies and Outcomes in Epidermal Growth Factor Receptor (EGFR) Oncogene‐Driven Stage IV Non‐Small Cell Lung Cancer, Following a First‐Line EGFR‐TKI Therapy

Cancer Reports, Volume 8, Issue 12, December 2025.
ABSTRACT Background Oncogene‐driven metastatic non‐small cell lung cancer (mNSCLC) is associated with poor survival outcomes, despite advancements in first‐line tyrosine kinase inhibitor (TKI) therapies. Aims This study aimed to characterise second‐line treatment strategies for epidermal growth factor receptor (EGFR)‐driven mNSCLC, and to evaluate ...
Meghana Maddula, Annelise Decaria, Bea Brown, John Simes, Michael Boyer, Venessa Chin   +5 more
wiley   +1 more source

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

Case Reports in Oncology, 2016
Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative ...
Shao-Lun Lu, Feng-Ming Hsu, Kuan-Yu Chen, Chao-Chi Ho, James Chih-Hsin  Yang, Jason Chia-Hsien Cheng   +5 more
doaj   +1 more source

Progression and Metastasis of Lung Cancer: Clinical Features, Molecular Mechanisms, and Clinical Managements

MedComm, Volume 6, Issue 12, December 2025.
Lung cancer represents a significant global health threat. Despite progress in treatment, metastasis continues to present a major clinical challenge. This article reviews the metastases of lung cancer to the liver, bone, and brain, focusing on clinical symptoms, molecular mechanisms, and treatment strategies.
Yunkui Zhang, Meixi Chen, Xumeng Fang, Yu Han, Yingke Li   +4 more
wiley   +1 more source